Related Experiment Video

Updated: Jul 15, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

106

The effect of dapagliflozin on anemia in elderly patients with heart failure by bioinformatics analysis

Feixing Li, Huixian Li, Fangjiang Li

    Technology and Health Care : Official Journal of the European Society for Engineering and Medicine
    |October 2, 2023
    PubMed

    Insights

    Dapagliflozin may impact anemia in elderly heart failure patients by targeting key genes like AKT1. This bioinformatics study identified 134 target genes and potential pathways, offering new insights into treatment strategies.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacogenomics
    • Bioinformatics

    Background:

    • Anemia is common in heart failure patients, worsening symptoms.
    • Dapagliflozin, an SGLT-2 inhibitor, shows cardiovascular benefits.
    • The effect of dapagliflozin on anemia in elderly heart failure patients remains unclear.

    Purpose of the Study:

    • To investigate the effect of dapagliflozin on anemia in elderly patients with heart failure using bioinformatics.
    • To identify potential molecular targets and pathways involved in this interaction.

    Main Methods:

    • Bioinformatics analysis to determine dapagliflozin target genes.
    • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis.
    • Construction of protein-protein interaction (PPI) networks and molecular docking simulations.

    Main Results:

    • Identified 134 target genes for dapagliflozin in heart failure-associated anemia.
    • Key pathways implicated include lipid metabolism, AGE-RAGE signaling, and insulin signaling.
    • Hub genes identified: AKT1, TP53, GAPDH, TNF, CASP3, EGFR, and MAPK3.
    • Molecular docking confirmed interaction between dapagliflozin and AKT1.

    Conclusions:

    • Dapagliflozin's effect on anemia in elderly heart failure patients involves multiple molecular pathways.
    • Hub genes like AKT1 are critical targets for dapagliflozin's action.
    • Further research is warranted to validate these findings and explore therapeutic potential.
    Abstract

    Keywords:
    AKT1Dapagliflozinanemiabioinformatics analysisheart failure

    More Related Videos

    Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management05:35

    Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

    Published on: January 19, 2024

    850
    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

    Published on: November 29, 2024

    650

    Related Concept Videos

    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    12
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    454
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    204
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    16
    Renal Failure: Dose Adjustments01:11

    Renal Failure: Dose Adjustments

    In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
    Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
    However, dosage adjustments...
    109
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    14